By George Ongkojoyo 
A landmark study published on January 16 in The Lancet Obstetrics, Gynaecology & Women’s Health has provided the most definitive evidence to date regarding the safety of acetaminophen use during pregnancy. Led by a research team at City St George’s, University of London, the comprehensive systematic review and meta-analysis concluded that prenatal exposure to acetaminophen—widely known by the brand name Tylenol and the generic name paracetamol—does not increase the risk of autism, attention-deficit hyperactivity disorder (ADHD), or intellectual disability in children. This finding arrives at a critical juncture for maternal health, potentially settling years of scientific debate and public anxiety regarding one of the most common medications used by pregnant individuals worldwide.
The research was spearheaded by Professor Asma Khalil, a renowned expert in Obstetrics and Maternal Fetal Medicine. The team sought to address growing concerns that had permeated both medical literature and public discourse, fueled by observational studies suggesting a potential link between the drug and neurodevelopmental challenges. By synthesizing data from 43 previously published studies and employing rigorous statistical controls, the researchers have provided a robust rebuttal to these claims, reaffirming acetaminophen’s status as the first-line treatment for pain and fever during pregnancy.
The Context of the Controversy: From Consensus to Confusion
The safety of acetaminophen during pregnancy became a flashpoint of public health concern following a series of observational reports over the last decade. The controversy reached a peak in late 2021 and continued through late 2025, following high-profile claims suggesting that even moderate prenatal exposure could interfere with fetal brain development. These claims were often based on statistical correlations found in large-scale population datasets, which appeared to show a higher prevalence of autism and ADHD in children whose mothers reported taking the medication.
However, many of these earlier studies were criticized by the broader scientific community for significant methodological flaws. The primary issue was "confounding by indication"—the difficulty of determining whether a developmental outcome was caused by the medication itself or by the underlying condition (such as a high fever or chronic inflammatory pain) that necessitated the medication. Furthermore, those studies often failed to account for genetic factors or the home environment, both of which play substantial roles in neurodevelopment.
The study by City St George’s was specifically designed to bridge these gaps. By conducting a meta-analysis—a study of studies—the researchers were able to filter out low-quality data and focus on the most scientifically sound evidence available. This approach allowed for a much larger sample size and a more nuanced understanding of the variables at play.
Methodology: The Power of Sibling Comparisons
One of the most significant contributions of this new review is its emphasis on sibling comparison studies. In traditional observational research, scientists compare children from different families. This introduces a wide array of "noise" into the data, as families differ in their genetic makeup, socioeconomic status, diet, and parenting styles.
In contrast, sibling comparison studies look at two or more children born to the same mother, where one was exposed to acetaminophen in utero and the other was not. Because these children share approximately 50% of their genes and grow up in the same household environment, they serve as a built-in control group. This method allows researchers to isolate the effects of the medication from the effects of shared genetics and environmental factors.
The scope of the data analyzed was unprecedented:
- Autism: The researchers reviewed outcomes for 262,852 children.
- ADHD: The analysis included 335,255 children.
- Intellectual Disability: The team assessed data for 406,681 children.
Across these vast cohorts, the researchers found that when sibling comparisons were utilized, the previously observed links between acetaminophen and neurodevelopmental conditions vanished. This suggests that the "risks" identified in previous studies were likely the result of inherited traits or other maternal health factors rather than the drug itself.
Evaluating Study Quality and Bias
To ensure the integrity of their findings, the City St George’s team utilized the Quality In Prognosis Studies (QUIPS) tool. This standardized framework allows researchers to evaluate the risk of bias in six domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting.
Even when the researchers narrowed their focus exclusively to studies rated as having a "low risk of bias"—representing the highest tier of scientific evidence—the results remained consistent. No statistically significant link was found between acetaminophen use and neurodevelopmental disorders. Furthermore, the reassuring results held steady in studies that followed children for more than five years, suggesting that there are no delayed-onset risks that emerge as a child enters school age.
Insights from the Research Team
Professor Asma Khalil, who also serves as a Consultant Obstetrician, emphasized that the findings should provide immediate peace of mind to expectant parents. "Our findings suggest that previously reported links are likely to be explained by genetic predisposition or other maternal factors such as fever or underlying pain, rather than a direct effect of the paracetamol itself," Khalil stated.
She further noted the importance of paracetamol in clinical practice. "The message is clear—paracetamol remains a safe option during pregnancy when taken as guided. This is important as paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever, and so they should feel reassured that they still have a safe option to relieve them of their symptoms."
The research highlights a critical concept in epidemiology: correlation does not equal causation. If a mother takes acetaminophen because she has a high fever, and her child later develops a neurodevelopmental condition, the fever—which is known to cause inflammation and potentially affect fetal development—is a more likely culprit than the medication used to treat it.
The Risks of Untreated Conditions
A vital component of the researchers’ analysis involves the risks associated with not treating pain and fever during pregnancy. Maternal fever, especially during the first trimester, has been linked in numerous studies to an increased risk of neural tube defects and other congenital anomalies. High, prolonged fever can create a hostile environment for a developing fetus, potentially leading to long-term health complications.
Similarly, chronic, untreated pain can lead to increased maternal stress, high blood pressure, and poor sleep, all of which can negatively impact pregnancy outcomes. By confirming that acetaminophen is safe, the study ensures that pregnant individuals do not feel forced to endure these conditions without medical intervention out of fear of harming their child.
Broader Impact on Clinical Guidelines and Public Policy
The results of this meta-analysis align with the long-standing guidance of major global health organizations, including the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the UK’s National Health Service (NHS). These organizations have consistently maintained that acetaminophen is the safest pain reliever available for pregnant women, particularly because non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are contraindicated in the later stages of pregnancy due to risks to the fetal heart and kidneys.
Medical professionals anticipate that this study will lead to a stabilization of clinical advice. In recent years, some healthcare providers had become hesitant to recommend acetaminophen, or had caveated their recommendations with so many warnings that patients were left feeling anxious. This comprehensive review provides a solid foundation for doctors to offer clear, confident guidance.
Limitations and Future Research Directions
While the study is the most comprehensive of its kind, the authors acknowledged certain limitations in the existing body of evidence. Many of the sibling studies reviewed did not provide granular data on exactly when during the pregnancy the medication was taken (trimester-specific data), the exact dosage, or the duration of use. Additionally, there was insufficient data to determine if the medication affected male and female fetuses differently.
"While we can confidently say there is no overall link, more research is needed to understand the nuances of high-frequency versus occasional use," the researchers noted. Future studies that track medication use in real-time through digital logs, rather than relying on retrospective surveys, may help fill these remaining gaps.
Conclusion: Reaffirming Maternal Health Safety
The publication of this review in The Lancet Obstetrics, Gynaecology & Women’s Health marks a pivotal moment in maternal-fetal medicine. By debunking the purported link between acetaminophen and neurodevelopmental disorders through the use of high-quality sibling data, the researchers have restored confidence in a critical tool for prenatal care.
For the millions of people who experience pain or fever during pregnancy each year, the conclusion is one of reassurance: acetaminophen, when used as directed by healthcare providers, remains a safe and effective option. As the medical community moves forward, the focus can return to ensuring that pregnant patients receive timely and effective treatment for their symptoms, supported by the highest level of scientific evidence.